Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
复制标题
DOI：
--
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Jacqueline M. Katz;K. Hancock;V. Veguilla;Weimin Zhong;Xiuhua Lu;Hong Sun;Eboneé N. Butler;Libo Dong-;Feng Liu-;Zhu-Nan Li;Joshua DeVos;Paul Gargiullo;Nancy J. Cox
中科院分区：
文献类型：
--
作者：
Jacqueline M. Katz;K. Hancock;V. Veguilla;Weimin Zhong;Xiuhua Lu;Hong Sun;Eboneé N. Butler;Libo Dong-;Feng Liu-;Zhu-Nan Li;Joshua DeVos;Paul Gargiullo;Nancy J. Cox
截至2009年5月19日，在47个州和哥伦比亚特区共记录了5469例人类感染新型甲型H1N1流感病毒的确诊或疑似病例。此外，该病毒已蔓延到41个国家，在美国以外的国家报告的病例总数为4774例。由于生产新型甲型H1N1流感病毒疫苗将需要几个月的时间，因此确定接种季节性流感疫苗是否可能对新型甲型H1N1流感病毒提供任何保护是重要的。因此，疾病控制与预防中心利用以前疫苗研究期间收集的储存血清样本，评估了儿童和成人在接种2005-06、2006-07、2007-08或2008-09流感季节疫苗前后对新型甲型H1N1流感病毒的交叉反应抗体水平。结果表明，在接种疫苗前，儿童中不存在甲型H1N1流感病毒的交叉反应抗体。在成人中，在接种疫苗前，18岁至年龄组中有6%-9%的人检测到交叉反应抗体，而在60岁组中有33%的人检测到交叉反应抗体。以前对儿童接种四种季节性三价灭活流感疫苗(TIV)或减毒活流感疫苗(LAIV)中的任何一种，都没有引起对新型甲型H1N1流感病毒的交叉反应抗体反应。在成年人中，接种季节性TIV疫苗导致18岁至岁的人对新型甲型H1N1流感病毒的交叉反应抗体反应增加了两倍，而对季节性H1N1病毒株的交叉反应抗体反应增加了12倍至19倍；在60岁的成年人中没有观察到对新型甲型H1N1流感病毒的交叉反应抗体反应增加。这些数据表明，最近(2005-2009年)接种季节性流感疫苗不太可能引起对新型甲型H1N1流感病毒的保护性抗体反应。
As of May 19, 2009, a total of 5,469 confirmed or probable cases of human infection with a novel influenza A (H1N1) virus had been documented in 47 states and the District of Columbia. In addition, the virus had spread to 41 countries, with a total of 4,774 cases reported in countries outside the United States. Because producing a novel influenza A (H1N1) virus vaccine will take several months, determining whether receipt of seasonal influenza vaccine might offer any protection against the novel influenza A (H1N1) virus is important. Therefore, using stored serum specimens collected during previous vaccine studies, CDC assessed the level of cross-reactive antibody to the novel influenza A (H1N1) virus in cohorts of children and adults before and after they had been vaccinated with the 2005-06, 2006-07, 2007-08, or 2008-09 influenza season vaccines. The results indicated that before vaccination, no cross-reactive antibody to the novel influenza A (H1N1) virus existed among children. Among adults, before vaccination, cross-reactive antibody was detected in 6%--9% of those aged 18--64 years and in 33% of those aged >60 years. Previous vaccination of children with any of four seasonal trivalent, inactivated influenza vaccines (TIV) or with live, attenuated influenza vaccine (LAIV) did not elicit a cross-reactive antibody response to the novel influenza A (H1N1) virus. Among adults, vaccination with seasonal TIV resulted in a twofold increase in cross-reactive antibody response to the novel influenza A (H1N1) virus among those aged 18--64 years, compared with a twelvefold to nineteenfold increase in cross-reactive antibody response to the seasonal H1N1 strain; no increase in cross-reactive antibody response to the novel influenza A (H1N1) virus was observed among adults aged >60 years. These data suggest that receipt of recent (2005--2009) seasonal influenza vaccines is unlikely to elicit a protective antibody response to the novel influenza A (H1N1) virus.